0.501  0.001 (0.2%)		09-13 16:00
Open: 0.519 High: 0.519 Volume: 44,922		Pre. Close: 0.5 Low: 0.5 Market Cap: 4(M)

Short term
Mid term
Targets	6-month :	0.64	1-year :	0.69
Resists	First :	0.54	Second :	0.59
Pivot price	0.51
Supports	First :	0.47	Second :	0.39
MAs	MA(5) :	0.5	MA(20) :	0.51
	MA(100) :	0.65	MA(250) :	1.1
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	22	D(3) :	25
RSI	RSI(14): 45.3
52-week	High :	2.92	Low :	0.4

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ENVB ] has closed above bottom band by 26.1%. Bollinger Bands are 71.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 12 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.52 - 0.52	0.52 - 0.52
Low:	0.49 - 0.5	0.5 - 0.5
Close:	0.5 - 0.5	0.5 - 0.5

Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Wed, 04 Sep 2024
Enveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan

Mon, 12 Aug 2024
ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q2 2024 - InvestorPlace

Tue, 30 Jul 2024
Why Is Enveric Biosciences (ENVB) Stock Up 18% Today? - InvestorPlace

Mon, 15 Jul 2024
Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement - Business Wire

Mon, 15 Jul 2024
Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement - StockTitan

Tue, 14 May 2024
Advancing Mental Health Treatments: The Strategic Collaboration Between Enveric Biosciences and MindBio Therapeutics - Microdose Psychedelic Insights

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	9 (M)
Shares Float	9 (M)
Held by Insiders	2.9 (%)
Held by Institutions	5.6 (%)
Shares Short	332 (K)
Shares Short P.Month	2,450 (K)

EPS	-3.5
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.68
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-80.5 %
Return on Equity (ttm)	-206.2 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.11
Qtrly Earnings Growth	0 %
Operating Cash Flow	-10 (M)
Levered Free Cash Flow	-9 (M)

PE Ratio	-0.15
PEG Ratio	0
Price to Book value	0.72
Price to Sales	0
Price to Cash Flow	-0.45

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.